23 results
10-K
2016 FY
EX-10.19
ADAP
Adaptimmune Therapeutics Plc
13 Mar 17
Annual report
12:00am
) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit … or other proceeding, if such filing is made under seal. The Act further provides that: an individual who files a lawsuit for retaliation by an employer
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. The Act … further provides that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose
10-K
2016 FY
EX-10.18
ADAP
Adaptimmune Therapeutics Plc
13 Mar 17
Annual report
12:00am
) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. The Act further provides … that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
16 Dec 20
Departure of Directors or Certain Officers
5:01pm
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. The Act further provides … that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
1 Aug 19
New Executive Team Announced at Adaptimmune
7:22am
violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. The Act further … provides that: an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade
10-K
EX-10.20
mxjspm3u6s z9l0s
13 Mar 17
Annual report
12:00am
8-K
EX-10.01
gtru1 bo6y3
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.1
eyk7 t9v5alsy1
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.1
yauc8 2y00o9kg
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
10-K
g0zoz 9wpjq0
13 Mar 17
Annual report
12:00am
DRS
78e0r62
5 Feb 15
Draft registration statement
12:00am
S-4/A
3o3q4s
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm